Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Biomaterials. 2012 Jan 14;33(10):2952–2960. doi: 10.1016/j.biomaterials.2011.12.043

Figure 6. Relative biodistribution of C60-serPF in an animal model of primary liver cancer and in vivo nuclear localization.

Figure 6

Panel A. Fluorescence images from tumor (T), Liver (L), Intestine (I), Pancreatobiliary (P), Spleen (S), Kidney (K), Brain (B), bisected heart (H), and Lungs (Lu) of a mouse bearing an orthotopic liver tumor generated after injecting Hep3B cells into the liver. Panel B. Relative tissue distribution of C60-serPF in mouse tissues, demonstrating accumulation in most tissues at 16-hours and predominantly in the kidney, liver, and liver cancer. (n=3) Panel C. Pharmacokinetics of fullerene uptake in select tissues, suggesting early renal clearance and a delayed hepatic clearance. C60-serPF localizes to the brain and tumor within 16 hours and persists for more than one week (one mouse per time point represented).